Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial (vol 401, pg 1655, 2023)

被引：1
作者：
Shitara, K.
Lordick, F.
Bang, Y-J
机构：
来源：
LANCET | 2023年 / 402卷 / 10398期
关键词：
D O I：
10.1016/S0140-6736(23)01481-2
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：290 / 290
页数：1
相关论文
共 1 条
  • [1] Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro- oesophageal junction adenocarcinoma (SPOTLIGHT) : a multicentre, randomised, double-blind, phase 3 trial
    Shitara, Kohei
    Lordick, Florian
    Bang, Yung-Jue
    Enzinger, Peter
    Ilson, David
    Shah, Manish A.
    Van Cutsem, Eric
    Xu, Rui-Hua
    Aprile, Giuseppe
    Xu, Jianming
    Chao, Joseph
    Pazo-Cid, Roberto
    Kang, Yoon-Koo
    Yang, Jianning
    Moran, Diarmuid
    Bhattacharya, Pranob
    Arozullah, Ahsan
    Park, Jung Wook
    Oh, Mok
    Ajani, Jaffer A.
    [J]. LANCET, 2023, 401 (10389) : 1655 - 1668
1